Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes Provided by PR Newswire Nov 18, 2025, 12:51:00 PM23 Nov 2025 19:20
Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
PR Newswire
NEW YORK, Nov. 18, 2025
New results and three presentations at ASN Kidney Week underscore kidneyintelX.dkd as a precision-medicine standard for CKD
NEW YORK, Nov. 18, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision-medicine diagnostics company for kidney health and developer of kidneyintelX.dkd, the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in chronic kidney disease (CKD), announced the publication of pivotal new data in Diabetes Care, the top-ranked global diabetes journal of the American Diabetes Association.
The published manuscript, "Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association with Kidney Outcomes in the CANVAS and CREDENCE Trials," was authored by leading nephrology and metabolism experts from the US, Europe, and Australia. The study evaluated 2,954 patients from the landmark CANVAS and CREDENCE trials—representing the full intended-use population for kidneyintelX.dkd.
Key Findings
Improved CKD risk prediction: kidneyintelX.dkd significantly enhanced risk stratification across all KDIGO guideline categories, delivering more accurate assessment of CKD progression risk and potential kidney failure.
Actionable treatment guidance: Among patients classified as moderate or high risk, those treated with frontline SGLT2 inhibitors showed a significant reduction in kidneyintelX.dkd risk levels at one year, with high-risk patients twice as likely to show risk improvement compared with untreated patients.
The authors concluded that kidneyintelX.dkd, and its novel kidney biomarkers, enables clinicians to identify patients most likely to benefit from therapy, supporting personalized risk-based care today and offering a powerful tool for future clinical trials.
Expert Perspective
Associate Professor Brendon Neuen of The George Institute for Global Health, Sydney, an internationally recognized expert in cardio-kidney-metabolic health and co-author of the study, commented:
"With multiple recent breakthroughs in therapies to reduce kidney function decline, the time for risk-based implementation in CKD has arrived. Incorporating novel biomarkers, as done with kidneyintelX.dkd, holds strong promise to guide risk-based care. These data provide a compelling example of how we can build on well-established clinical parameters to deliver more personalized care and reduce the risk of adverse outcomes."
Dr. Neuen serves as Program Lead, Renal & Metabolic at The George Institute and Director of Kidney Trials at Royal North Shore Hospital.
kidneyintelX.dkd Spotlighted in Three Presentations at ASN Kidney Week 2025
Renalytix also presented three new abstracts
Sign In
Follow the stocks
